06.09.14
Glanbia Nutritionals (NA), Inc., Carlsbad, CA, a global ingredient solutions and nutritional premix company, has unveiled an agreement with Ajinomoto Co., Inc,Raleigh, NC, a food and amino acid company, with regard to the exclusive distributorship of CapsiAtra for targeted markets in the U.S.
CapsiAtra is a dihydrocapsiate compound naturally found in CH-19 sweet peppers that holds clinical benefits in weight management, endurance and metabolism. CapsiAtra provides a new weight management and sports nutrition solution for easy inclusion in ready-to-mix, capsule and tablet applications. In addition to numerous human clinical trials, CapsiAtra has also received a letter of no objection from the FDA in regards to its GRAS safety dossier.
“As an innovative ingredient with impressive scientific support, CapsiAtra will be an excellent addition to our product line,” said Kevin Meyer, vice president of Sales and Business Development for Glanbia Nutritionals. “We’re excited to work with Ajinomoto to increase their current market presence and expand into new territories.”
“We are very pleased with our strategic partnership with Glanbia Nutritionals in terms of one of our most valuable specialty ingredients: CapsiAtra,” said Tak Kuwashima, general manager of Ajinomoto Co., Inc. “Glanbia’s nutritional expertise and sales team will open doors for CapsiAtra and allow us to enter into new and innovative markets that have been longing for scientifically proven ingredients in terms of both safety and efficacy.”
Glanbia and Ajinomoto will work closely to introduce CapsiAtra into innovative and novel applications, resulting in CapsiAtra’s inclusion in a variety of food and beverage weight management products and sports nutrition supplements.
CapsiAtra is a dihydrocapsiate compound naturally found in CH-19 sweet peppers that holds clinical benefits in weight management, endurance and metabolism. CapsiAtra provides a new weight management and sports nutrition solution for easy inclusion in ready-to-mix, capsule and tablet applications. In addition to numerous human clinical trials, CapsiAtra has also received a letter of no objection from the FDA in regards to its GRAS safety dossier.
“As an innovative ingredient with impressive scientific support, CapsiAtra will be an excellent addition to our product line,” said Kevin Meyer, vice president of Sales and Business Development for Glanbia Nutritionals. “We’re excited to work with Ajinomoto to increase their current market presence and expand into new territories.”
“We are very pleased with our strategic partnership with Glanbia Nutritionals in terms of one of our most valuable specialty ingredients: CapsiAtra,” said Tak Kuwashima, general manager of Ajinomoto Co., Inc. “Glanbia’s nutritional expertise and sales team will open doors for CapsiAtra and allow us to enter into new and innovative markets that have been longing for scientifically proven ingredients in terms of both safety and efficacy.”
Glanbia and Ajinomoto will work closely to introduce CapsiAtra into innovative and novel applications, resulting in CapsiAtra’s inclusion in a variety of food and beverage weight management products and sports nutrition supplements.